Clinical alert - thrombosis with thrombocytopaenia syndrome (TTS) update
For detailed information, read the
Australian Technical Advisory Group on Immunisation (ATAGI) clinical guidance on COVID-19 vaccine in Australia in 2021.
These are supporting documents for the
NSW Health Policy Directive PD2021_048 - Standard operating procedure for administration of COVID-19 vaccines in NSW vaccination clinics (updated 21 December 2021).
The form below should only be completed by medical practitioners if:
If a person has had COVID-19 and has fully recovered, there is no need to delay vaccination. The medical clearance notice provided to the person can be used as a temporary exemption from vaccination for 6 weeks only.
Medical practitioners should consult the latest
ATAGI clinical guidance for further information on medical contraindications:
For use by medical practitioners:
Joint statement from ATAGI and THANZ on Thrombosis with Thrombocytopenia Syndrome (TTS) and the use of COVID-19 Vaccine AstraZeneca
Serious Adverse Events Following Immunisation (AEFI) are notifiable conditions in NSW. Healthcare providers are required to report any serious AEFI to NSW Health and the Therapeutic Goods Administration.
Training modules are available for clinical staff including:
A multi-dose vial training module will be made available soon.